Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;28(6):661-72.
doi: 10.1111/pcmr.12412.

Genetics of melanocytic nevi

Affiliations
Review

Genetics of melanocytic nevi

Mi Ryung Roh et al. Pigment Cell Melanoma Res. 2015 Nov.

Abstract

Melanocytic nevi are a benign clonal proliferation of cells expressing the melanocytic phenotype, with heterogeneous clinical and molecular characteristics. In this review, we discuss the genetics of nevi by salient nevi subtypes: congenital melanocytic nevi, acquired melanocytic nevi, blue nevi, and Spitz nevi. While the molecular etiology of nevi has been less thoroughly studied than melanoma, it is clear that nevi and melanoma share common driver mutations. Acquired melanocytic nevi harbor oncogenic mutations in BRAF, which is the predominant oncogene associated with melanoma. Congenital melanocytic nevi and blue nevi frequently harbor NRAS mutations and GNAQ mutations, respectively, while Spitz and atypical Spitz tumors often exhibit HRAS and kinase rearrangements. These initial 'driver' mutations are thought to trigger the establishment of benign nevi. After this initial phase of the cell proliferation, a senescence program is executed, causing termination of nevi growth. Only upon the emergence of additional tumorigenic alterations, which may provide an escape from oncogene-induced senescence, can malignant progression occur. Here, we review the current literature on the pathobiology and genetics of nevi in the hope that additional studies of nevi promise to inform our understanding of the transition from benign neoplasm to malignancy.

Keywords: Spitz nevi; acquired melanocytic nevi; blue nevi; congenital melanocytic nevi; genetics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors state no conflicts of interest.

Figures

Figure 1
Figure 1. The RAS Signaling pathways and Nevi
MAPK signaling promotes cell growth and survival and is constitutively active in nevi. RAS family members are activated by receptor tyrosine kinases and signal through effector proteins, including RAF kinases and PI3K. Acquired melanocytic nevi harbor oncogenic mutations in BRAF, which is the predominant oncogene associated with melanoma. Congenital melanocytic nevi, blue nevi, and Spitz nevi frequently harbor NRAS mutations, GNAQ mutations, and HRAS alterations, respectively (Modified from N Engl J Med. 2010 Sep 30;363(14):1352-60 Copyright © (2010) Massachusetts Medical Society. Reprinted with permission.)
Figure 2
Figure 2
Clinical images of nevi. Subtypes of nevi include large CMN (A), medium CMN (B), melanoma arising in CMN (C), intradermal nevus (D), acral junctional nevus (E), dysplastic nevus (F), blue nevus (G), and Spitz nevus (H).

References

    1. Argenziano G, Zalaudek I, Ferrara G, Hofmann-Wellenhof R, Soyer HP. Proposal of a new classification system for melanocytic naevi. The British journal of dermatology. 2007;157:217–227. - PubMed
    1. Barbacid M. ras genes. Annual review of biochemistry. 1987;56:779–827. - PubMed
    1. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. The American journal of pathology. 2000;157:967–972. - PMC - PubMed
    1. Bastian BC, Wesselmann U, Pinkel D, Leboit PE. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. The Journal of investigative dermatology. 1999;113:1065–1069. - PubMed
    1. Bataille V. Genetic epidemiology of melanoma. European journal of cancer. 2003;39:1341–1347. - PubMed

Publication types

MeSH terms